- Home
- ASA vs TRVI Comparison
ASA vs TRVI Comparison
Compare ASA & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- TRVI
- Stock Information
- Founded
- ASA 1958
- TRVI 2011
- Country
- ASA United States
- TRVI United States
- Employees
- ASA N/A
- TRVI N/A
- Industry
- ASA Precious Metals
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- ASA Industrials
- TRVI Health Care
- Exchange
- ASA Nasdaq
- TRVI Nasdaq
- Market Cap
- ASA 415.9M
- TRVI 383.4M
- IPO Year
- ASA N/A
- TRVI 2019
- Fundamental
- Price
- ASA $29.06
- TRVI $5.97
- Analyst Decision
- ASA
- TRVI Strong Buy
- Analyst Count
- ASA 0
- TRVI 8
- Target Price
- ASA N/A
- TRVI $17.56
- AVG Volume (30 Days)
- ASA 52.8K
- TRVI 4.5M
- Earning Date
- ASA 04-08-2025
- TRVI 03-18-2025
- Dividend Yield
- ASA 0.13%
- TRVI N/A
- EPS Growth
- ASA 1102.63
- TRVI N/A
- EPS
- ASA 6.06
- TRVI N/A
- Revenue
- ASA $2,140,037.00
- TRVI N/A
- Revenue This Year
- ASA N/A
- TRVI N/A
- Revenue Next Year
- ASA N/A
- TRVI N/A
- P/E Ratio
- ASA $4.95
- TRVI N/A
- Revenue Growth
- ASA N/A
- TRVI N/A
- 52 Week Low
- ASA $15.35
- TRVI $2.30
- 52 Week High
- ASA $30.98
- TRVI $7.39
- Technical
- Relative Strength Index (RSI)
- ASA 72.03
- TRVI 53.50
- Support Level
- ASA $26.93
- TRVI $6.22
- Resistance Level
- ASA $30.99
- TRVI $6.68
- Average True Range (ATR)
- ASA 0.98
- TRVI 0.35
- MACD
- ASA 0.21
- TRVI -0.10
- Stochastic Oscillator
- ASA 85.21
- TRVI 2.12
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.